Examples of Case Studies
Technomics Research Initiates Academic Collaboration to Meet Client Need for Economic Data
Aberrant Trial Results Overcome by Bayes Analysis
Company Made Medical Device That Decreased The Rate Of Infections in Traumatic Wounds
A company made a medical device that, in a randomized clinical trial, decreased the rate of infections in traumatic wounds treated in the emergency department.
The hospital buyers objected to the cost of the device. Dr. Martinson developed a pro forma which demonstrated that in uninsured patients, the device was cost-saving because it prevented additional hospital losses that would have occurred if infections had developed in these patients. The company reported that it enjoyed good adoption in hospitals serving populations with high uninsurance rates.
New Drug Developed to Treat Diabetic Wounds
Therapy for Incontinence Equally Effective and Less Costly Than Competitive Therapies
A medical device manufacturer developed a therapy for incontinence that was equally effective and less costly compared to a competitive therapy. In spite of this, insurers were sometimes reluctant to cover it.
Dr. Martinson developed a Markov model showing the cost-effectiveness of the company’s device compared to the competition. A paper from this study is under publication review, which the company believes will be received favorably by insurers.
New Cardiac Arrhythmia Therapy Saves Retreatment Costs
Disease Management Program Gets Heart Patients on Medication
A large pharmaceutical company developed a new antilipemic drug – one that helps control blood lipids – and offered a coronary-artery-disease-management program to managed care organizations (MCOs) that positioned the drug favorably on their formulary. The program consisted of mailings to the MCO’s physicians regarding the physicians’ patients who might benefit from an antilipemic drug, and to patients regarding the benefits of antilipemic therapy. MCOs questioned the effectiveness of the program.
Dr. Martinson compared the drug utilization of health plans that used the program to those that did not, including the change in utilization in the months following program adoption. The results showed that members in plans with the program were almost 3 times as likely to take the drugs as those in comparable plans without the program, and that 94% of the members who took the drugs continued taking them after 6 months. The company was successful in convincing the MCO to continue the program and position the drug favorably on the formulary.